ArticleGlobal medical genetics2025
Hierarchical clustering defines hypermethylated RSPO2 as early-stage potential biomarker in colorectal cancer.
Article in Global medical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetics and Molecular Mechanisms in Oral Squamous Cell Carcinoma: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early-stage diagnosis, absence of specific reliable biomarkers, and better clinical management of colorectal cancer (CRC) remain major challenges. The Rspondin2 (RSPO2) gene is one of the most potent enablers of Wnt signaling, having contrasting aspects in tumor development and progression. Aim: We aimed to identify the role of RSPO2 as a molecular biomarker by evaluating its methylation and expression profiles in CRC tissue samples to identify biomarker potential. Methodology: Combined bisulfite restriction analysis Results: RSPO2 was hypermethylated (33/52; 63.46 %) and significantly associated with early-stage (I+II, p = 0.04) CRC tissue and exhibited low RSPO2 expression (42/52; 80.76 %). Hierarchical clustering stratified the samples into two distinct clusters that share some significant clinical and molecular factors specific for cluster 1 such as LN status (p < 0.0001) and lymphovascular invasion (p = 0.0013) while staging (p < 0.0001) and RSPO2 methylation (p = 0.0402) in cluster 2, which are valuable for personalized medicine. K-M plot analysis showed that patients with low RSPO2 expression have poor disease-free survival but could not be a risk factor. Conclusion: RSPO2 may be a potential biomarker for early-stage detection and provide valuable insight into the diagnosis of patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.